More than 20 CEOs of leading medical device companies flew into Washington to urge Congress to ease regulatory burdens on the industry, according to a release by AdvaMed.
AdvaMed's "Competitiveness Agenda" proposes six changes to help make the industry more competitive, including improved early-stage R&D, more efficient and predictable FDA regulation, adequate reimbursement, fair access to foreign markets and changes in tax policies.
In supplemental comments, AdvaMed asked the IRS to make sure drug-device combination products are not made to pay both an excise tax and a prescription drug fee. The group also asked to exempt companies that build certain prepackaged surgical kits from extra taxes, arguing that such kits should not be considered a manufacturing activity in itself.
Read the release from AdvaMed.
Related Articles on AdvaMed:
AdvaMed Unveils Policy Recommendations Aimed at Protecting U.S. Medical Innovation
Medical Device Lobby Calls for 6 Changes in Federal Policy
Study: No Safety Benefit Recognized From Slower, Burdensome FDA Approval Process for Devices